Core Insights - Evofem Biosciences is set to launch PHEXX®, a hormone-free contraceptive vaginal gel, in the UAE by 2026 following favorable pricing certificates from the Emirates Drug Establishment [1][2][3] Group 1: Product Overview - PHEXX® is the first and only locally-acting contraceptive gel approved by the FDA, designed to be applied before intercourse and works by maintaining a vaginal pH that is inhospitable to sperm [4] - The product contains lactic acid, citric acid, and potassium bitartrate, and is applied using a pre-filled applicator [4] Group 2: Market Expansion - The issuance of pricing certificates is a significant step for Evofem to diversify its revenue streams and enter new markets, particularly in the GCC and MENA regions [2][3] - Pharma 1, Evofem's licensee, holds exclusive commercialization rights for PHEXX® and SOLOSEC® in six GCC states and plans to expand into 15 additional countries [3] Group 3: Regulatory and Commercial Strategy - Pharma 1 is responsible for all aspects of distribution, sales, marketing, and regulatory approvals for PHEXX® and SOLOSEC® in the licensed territory [3] - The company aims to submit PHEXX® for marketing approval in other licensed countries following its approval in the UAE [3]